Biomaterial-Based Particulate Drug Carriers - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 20

51. Gabizon, A., Shmeeda, H., Barenholtz, Y. (2003) Pharmacokinetics of
pegylated liposomal Doxorubicin: review of animal and human studies,
Clin. Pharmacokinet ., 42, pp. 419-436
52. Allen, T.M., Martin, F.J. (2004) Advantages of liposomal delivery systems
for anthracyclines, Semin. Oncol ., 31, 5-15.
53. Immordino, M.L., Dosio, F., Cattel, L. (2006) Stealth liposomes: review
of the basic science, rationale, and clinical applications, existing and
potential, Int. J. Nanomed ., 1, pp. 297-315.
54. Soloman, R., Gabizon, A.A. (2008) Clinical pharmacology of liposomal
anthracyclines: focus on pegylated liposomal doxorubicin. Clin.
Lymphoma Myeloma , 8, pp. 21-32.
55. Schneider, G.F. et al. (2009) Multifunctional cytotoxic stealth
nanoparticles. a model approach with potential for cancer therapy,
Nano Lett ., 9, pp. 636-642.
56. Grenader, T. el al ((2009) Long-term response to pegylated liposomal
doxorubicin in patients with metastatic soft tissue sarcomas, Anti-
Cancer Drugs , 20, pp. 15-20.
57. Torchilin, V. (2008) Antibody-modified liposomes for cancer
chemotherapy, Exp. Opin. Drug Deliv ., 5, pp. 1003-1025.
58. Gabizon, A. et al.(2010) Improved therapeutic activity of folate-
targeted liposomal doxorubicin in folate receptor-expressing tumor
models. Cancer Chemo. Pharm ., 66, pp. 43-52.
59. Petros, R.A., DeSimone, J.M. (2010) Strategies in the design of
nanoparticles for therapeutic applications, Nat. Rev. Drug Discov ., 9,
pp. 615-627.
60. Huang Y.-H. et al (2009) Nanoparticle-delivered suicide gene therapy
eff ectively reduces ovarian tumor burden in mice. Cancer Res . 69, pp.
6184-6191.
61. Ahmed, M. et al. (2010 ) Pharmacokinetics of doxorubicin after
intratumoral injection using a thermosensitive hydrogel in tumor-
bearing mice, J. Control. Release , 142, pp. 101-107.
62. Morishita, M., Peppas, N.A. (2006) Is the oral route possible for peptide
and protein drug delivery? Drug Discov. Today , 11, pp. 905-910.
63. Singh, R., Singh, H., Lillard, J.W. (2008) Past, present, and future
technologies for oral delivery of therapeutic proteins, J. Pharm. Sci ., 97,
pp. 2497-2523.
64. Muller, G. (2010) Oral delivery of protein drugs: driver for personalized
medicine? Curr. Issues Mol. Biol. , 13, pp. 13-24.
65. Arbit, E., Kidron, M. (2009) Oral insulin: the rationale for this approach
and current developments, J. Diab. Sci. Technol. , 3, pp. 562-567.